Sagimet Biosciences Inc. 8K

Sagimet Biosciences furnished an investor presentation detailing positive Phase 3 acne data and China NDA progress for denifanstat, its plans and funding to advance a U.S. Phase 3 acne trial and broader FASN inhibitor pipeline, and its current cash runway through 2028.

Sagimet Biosciences Inc. furnished an investor presentation (Exhibit 99.2) outlining its development strategy for fatty acid synthase (FASN) inhibitors, highlighting that its lead oral FASN inhibitor denifanstat achieved all primary and secondary endpoints and was generally well-tolerated in a Phase 3 trial for moderate to severe acne conducted by its Greater China licensee Ascletis, with an NDA for acne accepted by China’s NMPA in December 2025. The company plans, subject to regulatory consultation, to initiate a U.S. Phase 3 acne trial for denifanstat in the second half of 2026 and has mapped out a 12‑week, 800‑patient, randomized, placebo‑controlled design with a 40‑week open-label extension. Sagimet also reported a strong cash position of approximately $257.6 million as of June 30, 2026 (including a $175 million underwritten Series A common stock offering in April 2026), which it expects to fund operations through 2028 and through the denifanstat U.S. Phase 3 acne readout. In addition, Sagimet described progress with its follow‑on FASN inhibitor TVB‑3567, which received IND clearance in March 2025 and entered a first‑in‑human Phase 1 trial in June 2025 with results expected in 2026 and a planned Phase 2 acne trial thereafter, as well as prior positive Phase 2b data for denifanstat in MASH and a development path for a denifanstat‑resmetirom combination dependent on securing non‑dilutive funding.

Filing Facts

CIK

1400118

Ticker

SGMT

Form

8K

Source Type

fda

Accession

0001193125-26-343446

Alert Tier

6